225 related articles for article (PubMed ID: 37099340)
21. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia.
Topp MS; Gökbuget N; Zugmaier G; Klappers P; Stelljes M; Neumann S; Viardot A; Marks R; Diedrich H; Faul C; Reichle A; Horst HA; Brüggemann M; Wessiepe D; Holland C; Alekar S; Mergen N; Einsele H; Hoelzer D; Bargou RC
J Clin Oncol; 2014 Dec; 32(36):4134-40. PubMed ID: 25385737
[TBL] [Abstract][Full Text] [Related]
22. Blinatumomab for the treatment of adult acute lymphoblastic leukemia.
Dahl J; Mace M; Kantarjian H; Jabbour E
Drugs Today (Barc); 2015 Apr; 51(4):231-41. PubMed ID: 26020065
[TBL] [Abstract][Full Text] [Related]
23. High tumor burden before blinatumomab has a negative impact on the outcome of adult patients with B-cell precursor acute lymphoblastic leukemia. A real-world study by the GRAALL.
Cabannes-Hamy A; Brissot E; Leguay T; Huguet F; Chevallier P; Hunault M; Escoffre-Barbe M; Cluzeau T; Balsat M; Nguyen S; Pasquier F; Alexis M; Lheritier V; Pastoret C; Delabesse E; Clappier E; Dombret H; Boissel N
Haematologica; 2022 Sep; 107(9):2072-2080. PubMed ID: 35263986
[TBL] [Abstract][Full Text] [Related]
24. Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia.
Jabbour E; Zugmaier G; Agrawal V; Martínez-Sánchez P; Rifón Roca JJ; Cassaday RD; Böll B; Rijneveld A; Abdul-Hay M; Huguet F; Cluzeau T; Díaz MT; Vucinic V; González-Campos J; Rambaldi A; Schwartz S; Berthon C; Hernández-Rivas JM; Gordon PR; Brüggemann M; Hamidi A; Chen Y; Wong HL; Panwar B; Katlinskaya Y; Markovic A; Kantarjian H
Am J Hematol; 2024 Apr; 99(4):586-595. PubMed ID: 38317420
[TBL] [Abstract][Full Text] [Related]
25. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.
Goebeler ME; Knop S; Viardot A; Kufer P; Topp MS; Einsele H; Noppeney R; Hess G; Kallert S; Mackensen A; Rupertus K; Kanz L; Libicher M; Nagorsen D; Zugmaier G; Klinger M; Wolf A; Dorsch B; Quednau BD; Schmidt M; Scheele J; Baeuerle PA; Leo E; Bargou RC
J Clin Oncol; 2016 Apr; 34(10):1104-11. PubMed ID: 26884582
[TBL] [Abstract][Full Text] [Related]
26. Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia.
Gökbuget N; Zugmaier G; Dombret H; Stein A; Bonifacio M; Graux C; Faul C; Brüggemann M; Taylor K; Mergen N; Reichle A; Horst HA; Havelange V; Topp MS; Bargou RC
Leuk Lymphoma; 2020 Nov; 61(11):2665-2673. PubMed ID: 32619115
[TBL] [Abstract][Full Text] [Related]
27. Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
Gökbuget N; Kantarjian HM; Brüggemann M; Stein AS; Bargou RC; Dombret H; Fielding AK; Heffner L; Rigal-Huguet F; Litzow M; O'Brien S; Zugmaier G; Gao S; Nagorsen D; Forman SJ; Topp MS
Blood Adv; 2019 Oct; 3(20):3033-3037. PubMed ID: 31648325
[TBL] [Abstract][Full Text] [Related]
28. Activity of blinatumomab in lymphoblastic leukemia with impaired T-cell immunity due to congenital immunodeficiency.
Ramdeny S; Chaudhary A; Worth A; Ghorashian S; Slatter M; Lum SH; Vora A
Blood Adv; 2021 Apr; 5(8):2153-2155. PubMed ID: 33881461
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of blinatumomab: Post hoc pooled analysis in Asian adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
Kobayashi Y; Oh I; Miyamoto T; Lee WS; Iida H; Minami H; Maeda Y; Jang JH; Yoon SS; Yeh SP; Tran Q; Morris J; Franklin J; Kiyoi H
Asia Pac J Clin Oncol; 2022 Jun; 18(3):311-318. PubMed ID: 34185953
[TBL] [Abstract][Full Text] [Related]
30. Extramedullary relapse and discordant CD19 expression between bone marrow and extramedullary sites in relapsed acute lymphoblastic leukemia after blinatumomab treatment.
Demosthenous C; Lalayanni C; Iskas M; Douka V; Pastelli N; Anagnostopoulos A
Curr Probl Cancer; 2019 Jun; 43(3):222-227. PubMed ID: 29895435
[TBL] [Abstract][Full Text] [Related]
31. CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy.
Pillai V; Muralidharan K; Meng W; Bagashev A; Oldridge DA; Rosenthal J; Van Arnam J; Melenhorst JJ; Mohan D; DiNofia AM; Luo M; Cherian S; Fromm JR; Wertheim G; Thomas-Tikhonenko A; Paessler M; June CH; Luning Prak ET; Bhoj VG; Grupp SA; Maude SL; Rheingold SR
Blood Adv; 2019 Nov; 3(22):3539-3549. PubMed ID: 31738832
[TBL] [Abstract][Full Text] [Related]
32. Pediatric patients with acute lymphoblastic leukemia treated with blinatumomab in a real-world setting: Results from the NEUF study.
Locatelli F; Maschan A; Boissel N; Strocchio L; Alam N; Pezzani I; Brescianini A; Kreuzbauer G; Baruchel A
Pediatr Blood Cancer; 2022 Apr; 69(4):e29562. PubMed ID: 35044079
[TBL] [Abstract][Full Text] [Related]
33. Outcomes for Australian children with relapsed/refractory acute lymphoblastic leukaemia treated with blinatumomab.
Sutton R; Pozza LD; Khaw SL; Fraser C; Revesz T; Chamberlain J; Mitchell R; Trahair TN; Bateman CM; Venn NC; Law T; Ong E; Heatley SL; McClure BJ; Meyer C; Marschalek R; Henderson MJ; Cross S; White DL; Kotecha RS
Pediatr Blood Cancer; 2021 May; 68(5):e28922. PubMed ID: 33638292
[TBL] [Abstract][Full Text] [Related]
34. Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults.
Foà R; Bassan R; Vitale A; Elia L; Piciocchi A; Puzzolo MC; Canichella M; Viero P; Ferrara F; Lunghi M; Fabbiano F; Bonifacio M; Fracchiolla N; Di Bartolomeo P; Mancino A; De Propris MS; Vignetti M; Guarini A; Rambaldi A; Chiaretti S;
N Engl J Med; 2020 Oct; 383(17):1613-1623. PubMed ID: 33085860
[TBL] [Abstract][Full Text] [Related]
35. Blinatumomab activity in a patient with Down syndrome B-precursor acute lymphoblastic leukemia.
Wadhwa A; Kutny MA; Xavier AC
Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 28921818
[TBL] [Abstract][Full Text] [Related]
36. Blinatumomab is associated with favorable outcomes in patients with B-cell lineage acute lymphoblastic leukemia and positive measurable residual disease at a threshold of 10
Jabbour EJ; Short NJ; Jain N; Jammal N; Jorgensen J; Wang S; Wang X; Ohanian M; Alvarado Y; Kadia T; Sasaki K; Garris R; Garcia-Manero G; Ravandi F; Kantarjian HM
Am J Hematol; 2022 Sep; 97(9):1135-1141. PubMed ID: 35713551
[TBL] [Abstract][Full Text] [Related]
37. The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades.
Jabbour E; Short NJ; Jain N; Haddad FG; Welch MA; Ravandi F; Kantarjian H
J Hematol Oncol; 2023 Mar; 16(1):22. PubMed ID: 36927623
[TBL] [Abstract][Full Text] [Related]
38. Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study.
Martinelli G; Boissel N; Chevallier P; Ottmann O; Gökbuget N; Rambaldi A; Ritchie EK; Papayannidis C; Tuglus CA; Morris JD; Stein A
Eur J Cancer; 2021 Mar; 146():107-114. PubMed ID: 33588145
[TBL] [Abstract][Full Text] [Related]
39. Blinatumomab: A novel, bispecific, T-cell engaging antibody.
May MB; Glode A
Am J Health Syst Pharm; 2016 Jan; 73(1):e6-e13. PubMed ID: 26683683
[TBL] [Abstract][Full Text] [Related]
40. Taking a "BiTE out of ALL": blinatumomab approval for MRD-positive ALL.
Curran E; Stock W
Blood; 2019 Apr; 133(16):1715-1719. PubMed ID: 30796026
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
